Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

pureCTC

Financiado

Cerrado

A LAB ON A CHIP DEVICE FOR PURE CIRCULATING TUMOR CELL ISOLATION FROM WHOLE BLOO...

A LAB ON A CHIP DEVICE FOR PURE CIRCULATING TUMOR CELL ISOLATION FROM WHOLE BLOOD FOR CANCER THERAPY The overall objective of pureCTC is to realize a comprehensive lab-on-a-chip platform that redefines the state-of-the-art technology to address all the requirements for fast, efficient and reliable CTC isolation/purification from... ver más

31/07/2019

VUB

173K€

Presupuesto del proyecto: 173K€

Líder del proyecto

VRIJE UNIVERSITEIT BRUSSEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-07-31

MSCA-IF-2016: Individual Fellowships

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

VUB

172.80K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CTCapture_2.0 Advanced platform for profiling of therapeutic targets and f... 150K€ Cerrado

CYTOPRO Profiling of tumour cells in blood for personalized treatmen... 71K€ Cerrado

MIRACLE Magnetic Isolation and moleculaR Analysis of single CircuLat... 9M€ Cerrado

CanDo A CANcer Development mOnitor 5M€ Cerrado

PTA2017-14934-I Detección y aislamiento de células únicas de muestras de tum... 36K€ Cerrado

MAINTRAC-Auto MAINTRAC Auto Automatization and validation of a liquid bio... 71K€ Cerrado

Duración del proyecto: 28 meses Fecha Inicio: 2017-03-14
Fecha Fin: 2019-07-31

Líder del proyecto

VRIJE UNIVERSITEIT BRUSSEL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 173K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The overall objective of pureCTC is to realize a comprehensive lab-on-a-chip platform that redefines the state-of-the-art technology to address all the requirements for fast, efficient and reliable CTC isolation/purification from whole blood. CTCs are rare cells that originate from tumors, and which travel in the human circulatory system to eventually spread the disease to other organs. Consequently, analysis of CTCs is crucial for revealing the mechanisms of cancer and developing new treatments. However, only 1-10 CTCs are present per mL of blood against billions of peripheral blood cells. The extreme rarity and inherent heterogeneity of CTCs implies a single-cell analysis strategy. Therefore, a highly selective, efficient and reliable system yet providing high throughput is mandatory. Cell labeling based strategies are inefficient for CTC analysis, since CTCs express biomarkers with high heterogeneity. Label-free methods based on size lack the ability to distinguish CTCs from leukocytes, and methods based on electrical properties fail to provide sufficient enrichment or throughput levels. To address these challenges, pureCTC proposes the development a microfluidic platform for successive enrichment, identification, and isolation of CTCs at the single-cell level, where a blood sample taken from a patient is directly injected and utilized without any pre-treatment. Namely, the platform is composed of 3 modules that work in tandem, each of them having innovative aspects: enrichment via 2D hydrodynamic-dielectrophoretic separation, identification via synchronous electro-optical detection, and isolation via a dielectrophoretic valve. The proposed research will undoubtedly contribute to the knowledge-based economy and European society, specifically on cancer research by providing an instrumental platform for diagnosis, monitoring and treatment of diseases with unprecedented selectivity, and enabling the advancement of personalized treatments.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores